We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+54.5%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$583M
AUM Growth
+$84.1M
Cap. Flow
-$23.8M
Cap. Flow %
-4.08%
Top 10 Hldgs %
45.64%
Holding
119
New
32
Increased
28
Reduced
17
Closed
42

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$25.6M
2
ABVX
Abivax
ABVX
+$24.6M
3
TWST icon
Twist Bioscience
TWST
+$16.2M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$12.6M
5
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.9M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$63.7M
2
DNLI icon
Denali Therapeutics
DNLI
+$22.2M
3
IMVT icon
Immunovant
IMVT
+$21.1M
4
QURE icon
uniQure
QURE
+$18.5M
5
WVE icon
Wave Life Sciences
WVE
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
51
NewAmsterdam Pharma
NAMS
$3.58B
$2.56M 0.44%
73,106
-77,467
-51% -$2.82M
MBX
52
MBX Biosciences
MBX
$2.9B
$2.48M 0.42%
78,553
+3,553
+5% +$86.2K
QNCX icon
53
Quince Therapeutics
QNCX
$18.2M
$2.48M 0.42%
+3,696
New +$1.86M
AVTX icon
54
Avalo Therapeutics
AVTX
$955M
$2.46M 0.42%
+135,552
New +$2.29M
IVVD icon
55
Invivyd
IVVD
$211M
$2.44M 0.42%
989,822
+711,214
+255% +$1.48M
MGTX icon
56
MeiraGTx Holdings
MGTX
$1.14B
$2.29M 0.39%
287,689
+205,831
+251% +$1.71M
IVA
57
Inventiva
IVA
$1.06B
$2.17M 0.37%
467,242
+436,418
+1,416% +$2.03M
ABBV icon
58
AbbVie
ABBV
$450B
$2.13M 0.37%
+9,325
New +$2.12M
ADCT icon
59
ADC Therapeutics
ADCT
$164M
$1.77M 0.3%
502,570
+219,284
+77% +$890K
MPLT
60
MapLight Therapeutics
MPLT
$1.69B
$1.76M 0.3%
+100,000
New +$1.68M
PHVS icon
61
Pharvaris
PHVS
$2.42B
$1.62M 0.28%
+58,389
New +$1.41M
LEGN icon
62
Legend Biotech
LEGN
$4.52B
$1.59M 0.27%
+73,328
New +$2.1M
BLTE
63
Belite Bio
BLTE
$6.2B
$1.47M 0.25%
+9,163
New +$1.09M
XLO icon
64
Xilio Therapeutics
XLO
$58.1M
$1.3M 0.22%
+145,002
New +$1.52M
EVMN
65
Evommune Inc
EVMN
$409M
$1.17M 0.2%
+68,196
New +$1.28M
BBOT
66
BridgeBio Oncology
BBOT
$666M
$1.08M 0.19%
86,517
-100,097
-54% -$1.21M
SYRE icon
67
Spyre Therapeutics
SYRE
$8.71B
$1.06M 0.18%
+32,377
New +$846K
QURE icon
68
uniQure
QURE
$2.81B
$1.04M 0.18%
43,485
-478,670
-92% -$18.5M
TSHA icon
69
Taysha Gene Therapies
TSHA
$1.64B
$1M 0.17%
182,130
-657,539
-78% -$3.19M
GLUE icon
70
Monte Rosa Therapeutics
GLUE
$2.03B
$966K 0.17%
+61,577
New +$830K
SABS icon
71
SAB Biotherapeutics
SABS
$266M
$548K 0.09%
+146,558
New +$482K
VNDA icon
72
Vanda Pharmaceuticals
VNDA
$324M
$520K 0.09%
+58,989
New +$325K
CAPR icon
73
Capricor Therapeutics
CAPR
$1.11B
$515K 0.09%
+17,853
New +$233K
SRRK icon
74
CALL
Scholar Rock
SRRK
$6.28B
$485K 0.08%
277,000
+258,600
+1,405% +$9.7M
KTTA icon
75
Pasithea Therapeutics
KTTA
$16.9M
$458K 0.08%
+355,082
New +$312K
1 2
3
4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Stempoint Capital held 119 positions worth $583M, up 17% from $499M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Stempoint Capital withdrew a net $23.8M in Q4 2025, closing 42 positions and reducing 17 holdings. Its most notable exit was Wave Life Sciences, an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Twist Bioscience worth $16.4M.

  • Stempoint Capital's largest Q4 2025 buy was Twist Bioscience: 518,355 shares worth $16.4M.
  • Stempoint Capital added most to Arcellx in Q4 2025, an estimated $25.6M increase.
  • Stempoint Capital's biggest Q4 2025 reduction was Roivant Sciences, cutting an estimated $63.7M.
  • Stempoint Capital fully exited Wave Life Sciences in Q4 2025, selling an estimated $15.4M.
  • Stempoint Capital's ten largest holdings make up 46% of its $583M portfolio in Q4 2025.
  • Stempoint Capital opened 32 new positions and closed 42 in Q4 2025.
  • Stempoint Capital's portfolio value rose 17% quarter-over-quarter to $583M.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.